Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CV2CoV

X
Drug Profile

CV2CoV

Alternative Names: CV-2-CoV; CV2CoV - CureVac/GSK

Latest Information Update: 18 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureVac; GlaxoSmithKline
  • Developer CureVac; GSK
  • Class COVID-19 vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I COVID 2019 infections

Most Recent Events

  • 07 Mar 2023 CureVac completes a phase I trial in COVID-2019 infections (Prevention) in USA (IM) (NCT05260437)
  • 22 Apr 2022 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by CureVac
  • 12 Feb 2022 Pharmacodynamics data from a preclinical trial in COVID-2019 infections presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top